Skin probiotics to treat atopic dermatitis

Active Project Grant Awarded Last action

Award ID
R44AI179327
Recipient
Awarding agency
Obligated
$999,988

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 65% complete
Place of performance
California, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Atopic dermatitis (ad) is a chronic skin condition that significantly diminishes quality of life due to persistent itching and inflammation. The dysfunction of the skin barrier, largely attributed to the overactivity of key proteases, is a crucial factor in ad pathogenesis. Current therapeutic options, primarily based on immunomodulation, are expensive and carry notable risks. Moreover, they fail to correct the fundamental barrier defect, necessitating indefinite treatment and exposing patients to potential long-term side eeects. In response to this challenge, we have devised an innovative treatment approach utilizing a non-pathogenic bacterium, engineered to deliver a trio of targeted protease inhibitors directly to the compromised skin barrier. This method is orthogonal and complementary to current immunotherapy and could potentially transform long-term ad management. During our phase i sbir eeorts, we demonstrated the potential for our therapy to deliver and sustain a novel protease inhibitor with high eeicacy across the epidermis in both EX vivo and in vivo models. For phase II, we extend this foundation into a comprehensive multi-protease inhibitor-producing cell therapy. We plan to demonstrate its eeicacy in an atopic murine model specifically designed to mimic protease-driven barrier damage, propelling US toward our pre-IND meeting with the FDA. This proposal leverages the unique ability of our platform for continuous, localized production of therapeutic proteins, promising a groundbreaking advancement in ad treatment. If successful, this could significantly reduce the economic burden of ad therapies, providing a safer, more eeective, and cost-eeicient treatment alternative for millions aeected by this debilitating condition.

Quick answers

Who received award R44AI179327?

R44AI179327 was awarded to Resvita Bio Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 1, 2023.

How much is award R44AI179327 worth?

$999,988 has been obligated on R44AI179327.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login